Literature DB >> 15273137

Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.

John F Mohr1, Kevin W Finkel, John H Rex, Jose R Rodriguez, Gerhard J Leitz, Luis Ostrosky-Zeichner.   

Abstract

The pharmacokinetics of intravenous itraconazole (ITC) was studied in dialysis patients. Dialysis had no effect on the half-life and clearance of ITC or OH-ITC. However, dialysis allowed the clearance of hydroxypropyl-beta-cyclodextrin (HP-beta-CD). The area under the concentration-time curve from time zero to infinity (AUC(0- infinity)) for HP-beta-CD administered before dialysis was lower than the AUC(0- infinity) when it was administered after dialysis (P < 0.01). Administration of ITC intravenously just prior to hemodialysis appears to produce adequate systemic exposures of ITC and OH-ITC while allowing dialysis clearance of HP-beta-CD. Studies of multiple administrations are warranted.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15273137      PMCID： PMC478538          DOI： 10.1128/AAC.48.8.3151-3153.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.

Authors:  K Vandewoude; D Vogelaers; J Decruyenaere; P Jaqmin; K De Beule; A Van Peer; R Woestenborghs; K Groen; F Colardyn
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

2.  Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography.

Authors:  R Woestenborghs; W Lorreyne; J Heykants
Journal:  J Chromatogr       Date:  1987-01-23

3.  Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation.

Authors:  S C Szathmary
Journal:  J Chromatogr       Date:  1989-01-27

Review 4.  Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics.

Authors:  L Willems; R van der Geest; K de Beule
Journal:  J Clin Pharm Ther       Date:  2001-06       Impact factor: 2.512

5.  Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.

Authors:  M A Boogaerts; J Maertens; R Van Der Geest; A Bosly; J M Michaux; A Van Hoof; M Cleeren; R Wostenborghs; K De Beule
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 6.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

7.  Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection.

Authors:  Q Zhao; H Zhou; L Pesco-Koplowitz
Journal:  J Clin Pharmacol       Date:  2001-12       Impact factor: 3.126

8.  A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.

Authors:  H Zhou; M Goldman; J Wu; R Woestenborghs; A E Hassell; P Lee; A Baruch; L Pesco-Koplowitz; J Borum; L J Wheat
Journal:  J Clin Pharmacol       Date:  1998-07       Impact factor: 3.126
  8 in total
  4 in total

1.  In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation.

Authors:  J W Mouton; A van Peer; K de Beule; A Van Vliet; J P Donnelly; P A Soons
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

3.  Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.

Authors:  Philip D Worboys; Shekman L Wong; Steven L Barriere
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

4.  Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.

Authors:  Randall K Hoover; Martin Krsak; Kyle C Molina; Kairav Shah; Mark Redell
Journal:  Open Forum Infect Dis       Date:  2022-03-23       Impact factor: 3.835
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.